Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
National Taiwan University Hospital · Guangdong General Hospital · +31 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,578
total citations
- FWCI
- 165.80
- Percentile
- 100%
- References
- 29
Citations per year
Authors
28- JCJames Chih‐Hsin YangCorresponding
National Taiwan University Hospital
- YWYi‐Long Wu
Guangdong General Hospital, Guangdong Academy of Medical Sciences
- MSMartin Schüler
- MSMartin Sebastian
Goethe University Frankfurt, University Medical Center of the Johannes Gutenberg University Mainz, Johannes Gutenberg University Mainz
- SPSanjay Popat
Royal Marsden Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Afatinib
- Pemetrexed
- Lung cancer
- Internal medicine
- Adenocarcinoma
- Lung
- Gemcitabine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.